nuaxia | Blog

Suche

nuaxia

vor 3 Stunden4 Min. Lesezeit

Medscape Psychiatrist Compensation Report 2026

nuaxia

vor 3 Stunden4 Min. Lesezeit

Medscape General Surgeon Compensation Report 2026

nuaxia

vor 3 Stunden3 Min. Lesezeit

Merck KGaA Expands Life Sciences Business with $11.3bn Bio-Techne Acquisition

nuaxia

vor 3 Stunden4 Min. Lesezeit

Medscape Urologist Compensation Report 2026

nuaxia

vor 3 Stunden4 Min. Lesezeit

Medscape Internist Compensation Report 2026

nuaxia

vor 3 Stunden3 Min. Lesezeit

Ipsen bets up to $1.75bn on Kartos to strengthen myelofibrosis pipeline

nuaxia

vor 3 Stunden3 Min. Lesezeit

Zymeworks’ $929m bid for Theravance reshapes its revenue base

nuaxia

vor 3 Stunden2 Min. Lesezeit

FDA Approves First Regulatory T-Cell Therapy for Chronic GVHD Prevention

nuaxia

vor 3 Stunden3 Min. Lesezeit

Vivani Spins Out Brain-Computer Interface Business Through Nasdaq Reverse Merger

nuaxia

vor 3 Stunden2 Min. Lesezeit

European Commission Expands Approval of Novartis' Itvisma for Broader SMA Patient Population

nuaxia

vor 3 Stunden2 Min. Lesezeit

Ipsen Strengthens Rare Disease Pipeline with €700m Memo Therapeutics Acquisition

nuaxia

vor 4 Stunden2 Min. Lesezeit

Insilico Medicine and Takeda Expand AI Drug Discovery Collaboration in $600m Partnership

nuaxia

vor 4 Stunden2 Min. Lesezeit

Celea Therapeutics Secures $180m to Advance Phase III IPF Programme

nuaxia

vor 4 Stunden2 Min. Lesezeit

Thermo Fisher and Arcturus Partner to Advance Phase III ARCT-032 Cystic Fibrosis Programme

nuaxia

vor 4 Stunden2 Min. Lesezeit

Scribe Therapeutics Moves Toward Nasdaq Debut as CRISPR Pipeline Advances Into Clinic

nuaxia

vor 4 Stunden3 Min. Lesezeit

Novartis Acquires Myricx Bio in Up to $1.5bn Deal to Strengthen ADC Pipeline

nuaxia

vor 4 Stunden2 Min. Lesezeit

Roche Strengthens Breast Cancer Pipeline with $490m+ Astex Partnership

nuaxia

vor 4 Stunden3 Min. Lesezeit

UK Expands Wegovy Approval to Include MASH Treatment

nuaxia

vor 4 Stunden3 Min. Lesezeit

PureTech-Backed Celea Raises $180m to Challenge Established IPF Treatments

nuaxia

vor 4 Stunden2 Min. Lesezeit

Medscape Psychiatrist Compensation Report 2026

Medscape General Surgeon Compensation Report 2026

Merck KGaA Expands Life Sciences Business with $11.3bn Bio-Techne Acquisition

Medscape Urologist Compensation Report 2026

Medscape Internist Compensation Report 2026

Ipsen bets up to $1.75bn on Kartos to strengthen myelofibrosis pipeline

Zymeworks’ $929m bid for Theravance reshapes its revenue base

FDA Approves First Regulatory T-Cell Therapy for Chronic GVHD Prevention

Vivani Spins Out Brain-Computer Interface Business Through Nasdaq Reverse Merger

European Commission Expands Approval of Novartis' Itvisma for Broader SMA Patient Population

Ipsen Strengthens Rare Disease Pipeline with €700m Memo Therapeutics Acquisition

Insilico Medicine and Takeda Expand AI Drug Discovery Collaboration in $600m Partnership

Celea Therapeutics Secures $180m to Advance Phase III IPF Programme

Thermo Fisher and Arcturus Partner to Advance Phase III ARCT-032 Cystic Fibrosis Programme

Scribe Therapeutics Moves Toward Nasdaq Debut as CRISPR Pipeline Advances Into Clinic

Novartis Acquires Myricx Bio in Up to $1.5bn Deal to Strengthen ADC Pipeline

Roche Strengthens Breast Cancer Pipeline with $490m+ Astex Partnership

UK Expands Wegovy Approval to Include MASH Treatment

PureTech-Backed Celea Raises $180m to Challenge Established IPF Treatments

FDA Approves Trutakna as First Dual BAFF/APRIL Targeted Therapy for IgA Nephropathy